Strategy: Tracks the Nasdaq Biotechnology Index at a significantly lower price point . Expense Ratio: 0.19% .
Strategy: Actively managed by Cathie Wood's team, targeting "disruptive" innovation . Expense Ratio: 0.75% . Comparison of Key Metrics 1-Year Return Expense Ratio Small/Mid-Cap Equal Weight IBB Large-Cap Market Weighted SBIO Clinical Trial Breakthroughs IBBQ Nasdaq Biotech Index Data based on recent 2026 market reports . best biotech etf to buy now
Your (e.g., long-term stability vs. short-term growth)? Strategy: Tracks the Nasdaq Biotechnology Index at a
Best for: Concentrated exposure to the 25 largest, most liquid biotech stocks . Strategy: Focuses on profitable blue-chip biotechs . Expense Ratio: 0.35% . best biotech etf to buy now